Table 1.
Demographics and baseline characteristics. SAP: systolic arterial pressure; DAP: diastolic arterial pressure; MAP: median arterial pressure; LVEF: left ventricular ejection fraction; CHD: coronary heart disease; RRI: renal resistive index.
| Demographics and Characteristics | |
|---|---|
| Age (years) | 67 ± 13 |
| Female (%) | 26 |
| Male (%) | 74 |
| 1-vessel CHD (%) | 28 |
| 2-vessel CHD (%) | 26 |
| 3-vessel-CHD (%) | 36 |
| BMI | 26.4 ± 3.4 |
| SAP (mmHg) during measurements | 113 ± 19 |
| DAP (mmHg) during measurements | 60 ± 11 |
| MAP (mmHg) during measurements | 85.4 ± 17 |
| Baseline Creatinine (mg/dL) (at Impella® insertion) |
2.89 ± 2.8 |
| Impella® (days) | 9 ± 6 |
| Impella®-support (min/max. L/min) | 1.5/2.5 L/min ± 0.4 L/min |
| Noradrenaline (µg/kg/min) overall cohort | 0.12 ± 0.19 |
| Noradrenaline (µg/kg/min) RRI ≥ 0.8 | 0.36 ± 0.34 |
| Noradrenaline (µg/kg/min) RRI < 0.8 | 0.12 ± 0.24 |
| Dobutamine (µg/kg/min) overall cohort | 3.1 ± 2.67 |
| Dobutamine (µg/kg/min) RRI ≥ 0.8 | 5.9 ± 2.5 |
| Dobutamine (µg/kg/min) RRI < 0.8 | 3.9 ± 2.5 |
| Renal longitudinal length (cm) | 9.32 ± 1.1 |
| Renal parenchymal thickness (cm) | 2.1 ± 0.4 |
| LVEF at Impella® insertion (%) | 37 ± 18 |